دورة المؤشرنت للتحليل الفني
50 دينار كويتي
سهم MeLa طبي ومخترع جهاز لعلاج سرطان الجلد ونسبة نجاح تفوق 75% وينتظر ترفيع درجة والسهم مضغوط
- بادئ الموضوع aboshaher
- تاريخ البدء
الصريح والصحيح
موقوف
الله يعيناش الحل وياااه هالسم الخايس
خله لا تذكر المظاربين فيه ثم يشترون وينزل أكثر
aboshaher
عضو نشط
- التسجيل
- 21 نوفمبر 2013
- المشاركات
- 415
MELA Sciences Predictive Probability Study Supports Increased Diagnostic Accuracy by Dermatologists for Melanoma
MELA Sciences, Inc.45 minutes ago
IRVINGTON, NY--(Marketwired - May 8, 2014) - MELA Sciences, Inc. (NASDAQ:MELA), developer of theMelaFind®system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced statistically significant preliminary results of a study that measured the impact of predictive probability information (probability of lesion being melanoma and melanoma/high-grade) on dermatologists' decisions to biopsy ambiguous pigmented skin lesions.
Study OverviewAt the January 2014 Winter Clinical Dermatology Conference, 191 dermatologists reviewed images of 12 lesions in a reader study facilitated by Darrell S. Rigel, MD, MS. Dr. Rigel is a Clinical Professor of Dermatology at New York University, Langone Medical Center. The physicians were asked if they would biopsy each lesion before and after seeing the MelaFind system probability information, and then both sets of data were analyzed.
Study ResultsThe biopsy sensitivity of dermatologists increased from 68% to 89% with the addition of the MelaFind system probability information, and specificity increased from 39% to 54%. Sensitivity measures the percentage of lesions correctly identified as melanoma, and specificity measures the percentage of lesions correctly identified as not being melanoma. The average percentage of benign lesions selected for biopsy decreased from 61% to 46%. The p-value in all three measurements was statistically significant at p
Dr. Rigel, who facilitated the reader study, commented, "The preliminary results of this study are very compelling. The ability to improve diagnostic accuracy without increasing the rate of biopsies is very meaningful for physicians."
This data will be presented at the 2014 American Dermoscopy Meeting, June 17-19 in Bar Harbor, Maine.
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical device company developing dermatology diagnostics utilizing state-of-the-art optical imaging. The Company's flagship product is the MelaFind® system, a non-invasive diagnostic tool to aid dermatologists in melanoma evaluation and diagnosis, which has secured FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union. The MelaFind® system uses a variety of visible to near-infrared light waves to evaluate skin lesions from the surface to 2.5 mm beneath the skin. It provides images and data on the relative disorganization of a lesion's cell structure that provides substantial additional perspective to aid melanoma diagnosis. MELA is also exploring new potential uses for its core imaging technology and algorithms.
Safe HarborThis press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and may contain words such as "seeks," "look forward," and "there seems" that suggest future events or trends. These statements are based on our current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from our expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the company's SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. MELA Sciences assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at www.sec.gov andwww.melasciences.com.
Contact:
MediaDiana Garcia Redruello
MELA Sciences, Inc.
212-518-4226
Email Contact
InvestorsDavid Collins, Eric Lentini
Catalyst Global
212-924-9800
MELA Sciences, Inc.45 minutes ago
IRVINGTON, NY--(Marketwired - May 8, 2014) - MELA Sciences, Inc. (NASDAQ:MELA), developer of theMelaFind®system, an optical diagnostic device approved for use in the U.S. and the European Union to assist dermatologists in melanoma diagnosis, today announced statistically significant preliminary results of a study that measured the impact of predictive probability information (probability of lesion being melanoma and melanoma/high-grade) on dermatologists' decisions to biopsy ambiguous pigmented skin lesions.
Study OverviewAt the January 2014 Winter Clinical Dermatology Conference, 191 dermatologists reviewed images of 12 lesions in a reader study facilitated by Darrell S. Rigel, MD, MS. Dr. Rigel is a Clinical Professor of Dermatology at New York University, Langone Medical Center. The physicians were asked if they would biopsy each lesion before and after seeing the MelaFind system probability information, and then both sets of data were analyzed.
Study ResultsThe biopsy sensitivity of dermatologists increased from 68% to 89% with the addition of the MelaFind system probability information, and specificity increased from 39% to 54%. Sensitivity measures the percentage of lesions correctly identified as melanoma, and specificity measures the percentage of lesions correctly identified as not being melanoma. The average percentage of benign lesions selected for biopsy decreased from 61% to 46%. The p-value in all three measurements was statistically significant at p
Dr. Rigel, who facilitated the reader study, commented, "The preliminary results of this study are very compelling. The ability to improve diagnostic accuracy without increasing the rate of biopsies is very meaningful for physicians."
This data will be presented at the 2014 American Dermoscopy Meeting, June 17-19 in Bar Harbor, Maine.
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical device company developing dermatology diagnostics utilizing state-of-the-art optical imaging. The Company's flagship product is the MelaFind® system, a non-invasive diagnostic tool to aid dermatologists in melanoma evaluation and diagnosis, which has secured FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union. The MelaFind® system uses a variety of visible to near-infrared light waves to evaluate skin lesions from the surface to 2.5 mm beneath the skin. It provides images and data on the relative disorganization of a lesion's cell structure that provides substantial additional perspective to aid melanoma diagnosis. MELA is also exploring new potential uses for its core imaging technology and algorithms.
Safe HarborThis press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and may contain words such as "seeks," "look forward," and "there seems" that suggest future events or trends. These statements are based on our current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from our expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the company's SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. MELA Sciences assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at www.sec.gov andwww.melasciences.com.
Contact:
MediaDiana Garcia Redruello
MELA Sciences, Inc.
212-518-4226
Email Contact
InvestorsDavid Collins, Eric Lentini
Catalyst Global
212-924-9800
aboshaher
عضو نشط
- التسجيل
- 21 نوفمبر 2013
- المشاركات
- 415
تائج الدراسة
زيادة حساسية خزعة من الأمراض الجلدية والتناسلية من 68 ٪ إلى 89 ٪ مع إضافة معلومات النظام MelaFind الاحتمالات، وزيادة الدقة من 39٪ إلى 54 ٪ . يقيس حساسية النسبة المئوية لل آفات التي تم تحديدها بشكل صحيح كما سرطان الجلد، و يقيس خصوصية النسبة المئوية لل آفات التي تم تحديدها بشكل صحيح كما لا يجري سرطان الجلد. انخفض متوسط النسبة المئوية لل آفات حميدة اختيارها لخزعة من 61 ٪ إلى 46 ٪ . كانت القيمة p في جميع القياسات الثلاثة ذات دلالة إحصائية عند ع
وعلق الدكتور ريجل ، الذين سهلت دراسة القارئ، "إن النتائج الأولية ل هذه الدراسة هي مقنعة جدا. القدرة على تحسين دقة التشخيص دون زيادة معدل الخزعات هو مفيد جدا للأطباء ".
وسوف تعرض هذه البيانات في الاجتماع 2014 Dermoscopy الأمريكية ، 17-19 يونيو في بار هاربور ، مين .
زيادة حساسية خزعة من الأمراض الجلدية والتناسلية من 68 ٪ إلى 89 ٪ مع إضافة معلومات النظام MelaFind الاحتمالات، وزيادة الدقة من 39٪ إلى 54 ٪ . يقيس حساسية النسبة المئوية لل آفات التي تم تحديدها بشكل صحيح كما سرطان الجلد، و يقيس خصوصية النسبة المئوية لل آفات التي تم تحديدها بشكل صحيح كما لا يجري سرطان الجلد. انخفض متوسط النسبة المئوية لل آفات حميدة اختيارها لخزعة من 61 ٪ إلى 46 ٪ . كانت القيمة p في جميع القياسات الثلاثة ذات دلالة إحصائية عند ع
وعلق الدكتور ريجل ، الذين سهلت دراسة القارئ، "إن النتائج الأولية ل هذه الدراسة هي مقنعة جدا. القدرة على تحسين دقة التشخيص دون زيادة معدل الخزعات هو مفيد جدا للأطباء ".
وسوف تعرض هذه البيانات في الاجتماع 2014 Dermoscopy الأمريكية ، 17-19 يونيو في بار هاربور ، مين .
morganramadan
عضو نشط
- التسجيل
- 30 مارس 2014
- المشاركات
- 41
ياليت احد من الشباب الحلوين يشوف لنا ليش هالنزول للسهم
لان الصراحة اذا ما في مبرر للنزول اشوفه فرصة ممتازة للاستثمار المتوسط
لان الصراحة اذا ما في مبرر للنزول اشوفه فرصة ممتازة للاستثمار المتوسط
دورة المؤشرنت للتحليل الفني
50 دينار كويتي